- Previous: Stalling Hepatitis C In-Between Health Coverage
- Main
- Next: Inhibiting the Hepatitis C Virus
FDA Expands Use of Schering's Hepatitis C Drugs
March 16, 2009
While previously only approved for patients who had never taken any Hepatitis C drugs, Pegintron and Rebetol are now approved by the FDA for re-treatment.
Schering say FDA expands hepatitis drug labels
Associated Press, 03.11.09, 04:39 PM EST
The Food and Drug Administration expanded the label for Schering-Plough Corp.'s hepatitis C drugs Pegintron and Rebetol, allowing the company to market the drugs for patients who have not recovered from the disease after previous treatment.
Schering-Plough (nyse: SGP - news - people ) said Wednesday that the FDA approved the drugs for the treatment of chronic hepatitis C in patients with compensated liver disease. They were already approved for use in "treatment-naive" patients, or those who had never taken any drugs for the liver disease.
The drugs are approved for use in patients 3 and older.
The company said more than 100,000 people in the U.S. have received at least one unsuccessful treatment for hepatitis C. Sales of Pegintron totaled $914 million in 2008, and Schering-Plough reported $260 million in Rebetol revenue.
Schering-Plough on Monday accepted a buyout offer from Merck and Co. (nyse: MRK - news - people ) worth $41.1 billion.
Copyright 2009 by Associated Press
---
URL for Article Source:
http://www.forbes.com/feeds/ap/2009/03/11/ap6155863.html
Posted by Editors at March 16, 2009 4:09 PM
Site Topics
HCV Symptoms
You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.
Lab Tests
What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.
Hepatitis C Genotypes
Learn about Hepatitis C Genotypes and their variants.
Viral Load
Includes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.
What is...?
Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.
HCV Medicines
Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.
Hepatitis C Doctors
A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.
Biopsy Info
A comprehensive resource of information relating to the liver biopsy.
Cirrhosis
Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.
Liver Cancer
Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.
Liver Disease Medicines
An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.
Hep-Central Email List
Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.
HCV Links
Convenient links to other sites external to Hepatitis-Central.
Mother/Child Transmission
Discussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.
HCV Natural Remedies
A number of herbal products useful in the management of liver disease.
HCV Books
Recommended reading for those interested in hepatitis information.
Hepatitis C Forum
A Bulletin Board for discussions on hepatitis, treatments, etc.
Hepatitis C Activism
An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.
Advertisement
Advertisement
Site Topics
HCV Symptoms, Lab Tests, Hepatitis C Genotypes, Glossary, Viral Load, What is...?, HCV Medicines, Hepatitis C Doctors, Biopsy Info, Cirrhosis, Liver Cancer, Liver Disease Medicines, Hep-Central Email List, HCV Links, Mother / Child Transmission, HCV Natural Remedies, HCV Books, Hepatitis C Forum, Hepatitis C Activism
Copyright ©1994-2010 Hepatitis Central. Information at this website is for educational purposes only; statements about products and health conditions have not been evaluated by the U.S. Food & Drug Administration.